Expecto Health Science Pte. Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Expecto Health Science Pte. Ltd. - overview
Established
2023
Location
Singapore, -, Singapore
Primary Industry
Biotechnology
About
Based in Singapore and founded in 2023 and led by CEO Pramod Kashid, Expecto Health Science Pte. Ltd. operates as a B2B enterprise clinical research solutions provider. The company provides clinical trial operations, regulatory‑compliant clinical development services, and CRO solutions supporting pharmaceutical, biotechnology, and medical device sponsors across Asia‑Pacific.
In February 2026, Southern Star Research Pty Ltd, a portfolio company of Quadrant Private Equity, acquired Expecto Health Science Pte. Ltd. Expecto Health Science serves pharmaceutical, biotechnology, and medical device companies conducting clinical trials in Asia‑Pacific. The company's services include clinical operations, clinical project management, data management, medical writing, pharmacovigilance, regulatory strategy, and real‑world evidence (RWE) study management.
The firm 's services support trial execution and regulatory compliance. It also provides clinical research and development services for the life sciences industry. The company’s revenue is generated through B2B clinical research services, including contract research operations, project‑based clinical trial execution, regulatory and data management services, and related CRO engagements for life sciences sponsors. The company plans to use proceeds from its strategic investment by Southern Star Research (February 2026) to expand late‑phase clinical development capabilities, strengthen its Asia‑Pacific footprint, and enable seamless progression from early‑phase studies in Australia and New Zealand to later‑phase trials across key Asian markets.
Current Investors
Southern Star Research Pty Ltd
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Clinics/Outpatient Services
Website
www.expectohealthscience.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Expecto Health Science Pte. Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Expecto Health Science Pte. Ltd. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.